Champions Oncology (NASDAQ:CSBR – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
Volatility & Risk
Champions Oncology has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Champions Oncology and 10x Genomics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
| 10x Genomics | 1 | 12 | 5 | 0 | 2.22 |
10x Genomics has a consensus target price of $68.07, indicating a potential upside of 14.82%. Given 10x Genomics’ stronger consensus rating and higher probable upside, analysts plainly believe 10x Genomics is more favorable than Champions Oncology.
Valuation & Earnings
This table compares Champions Oncology and 10x Genomics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Champions Oncology | $59.42 million | 1.12 | -$1.17 million | ($0.08) | -59.88 |
| 10x Genomics | $642.82 million | 12.02 | -$43.54 million | ($0.59) | -100.47 |
Champions Oncology has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Champions Oncology, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 46.3% of Champions Oncology shares are owned by insiders. Comparatively, 8.8% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Champions Oncology and 10x Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Champions Oncology | -1.82% | -25.77% | -3.71% |
| 10x Genomics | -12.18% | -9.33% | -7.30% |
Summary
10x Genomics beats Champions Oncology on 8 of the 13 factors compared between the two stocks.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
